Agents in late-stage development of cystic fibrosis
The Cost of New Cancer Drugs is Increasing
The median annual cost for new oncology medicines launched in 2022 was $260,000, up from $63,534 10 years ago, an IQVIA report finds.
FDA to Review sBLA for Jemperli for Earlier Treatment of Endometrial Cancer
The FDA has assigned an action date of Sept. 23, 2023. If approved, this would be the first frontline treatment advancement in decades for patients with advanced or recurrent endometrial cancer.
New Heart Failure Drug Likely to be Cost-Effective in Hospitalized Patients
In an analysis, researchers determined that Inpefa is cost-effective at commonly accepted willingness-to-pay thresholds in treating patients with heart failure who have diabetes.
FDA Approves Prevymis for CMV Prevention in Kidney Transplant Patients
Prevymis was approved to prevent CMV infection in adults after an allogeneic hematopoietic stem cell transplant in 2017.
FDA Clears Lynparza for Prostate Cancer with High Mortality Risk
The combination of Lynparza and abiraterone reduced the risk of disease progression or death by 76% vs. abiraterone alone in patients with BRCA-mutated metastatic castration-resistant prostate cancer.
CMS Will Cover Alzheimer’s Drugs Leqembi, Donanemab — With Strings Attached
The drugs must have full “traditional” FDA approval and patients need to be enrolled in a registry that collects post-approval data efficacy and safety when the drugs are used in clinical practice.
2 Clarke Drive Cranbury, NJ 08512